SCHEMBL22200718

SCHEMBL22200718

CC(C)n1c(=O)cnc2cnc(N)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 7/20 0.40
PIK3CA P42336 6/20 0.39
CYP1A2 P05177 7/20 0.39
HSD17B10 Q99714 6/20 0.39
ALDH1A1 P00352 5/20 0.39
CASP1 P29466 4/20 0.39
CASP7 P55210 4/20 0.39
HPGD P15428 3/20 0.39
CYP2D6 P10635 1/20 0.39
USP2 O75604 3/20 0.37
CYP2C19 P33261 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ADRA1A P35348 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
GLA P06280 1/20 0.37
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CCND2 P30279 1/20 0.35
CCND3 P30281 1/20 0.35
RICTOR Q6R327 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22190717 0.81 CYP1A2 (0.39) CYP1A2HSD17B10ALDH1A1CASP1CASP7
SCHEMBL17807800 0.81 CYP1A2 (0.39) CYP1A2HSD17B10ALDH1A1CASP1CASP7
SCHEMBL30278828 0.78 KDM4E (0.38) CYP1A2HSD17B10ALDH1A1CASP1CASP7
SCHEMBL22190643 0.78 KDM4E (0.38) CYP1A2HSD17B10ALDH1A1CASP1CASP7
SCHEMBL5266289 0.77 CDK4 (0.57) CDK4CCND1CCND2CCND3
SCHEMBL34470301 0.76 RORC (0.35) MTORPIK3CAHSD17B10ALDH1A1HPGD
SCHEMBL27985202 0.75 CDK1 (0.35) MTORPIK3CAHSD17B10ALDH1A1HPGD
SCHEMBL17807802 0.73 CDK4 (0.37) MTORCYP1A2HSD17B10ALDH1A1CASP1
SCHEMBL22200437 0.73 MTOR (0.52) MTORPIK3CACYP1A2HSD17B10ALDH1A1
SCHEMBL22200463 0.72 MTOR (0.44) MTORPIK3CACYP1A2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed